Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Circulating Tumor Cell Stories

2011-08-24 12:32:00

SAN DIEGO, Aug. 24, 2011 /PRNewswire/ -- Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in cancer patients, and Clarient, Inc. (a GE Healthcare Company) today announced a collaboration on the commercialization of a proprietary blood test for CTCs in breast cancer patients, which includes the determination of HER2 status. Clarient and Biocept will market and sell Biocept's new OncoCEE-BR(TM)...

2011-07-28 18:05:00

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Biocept, Inc., an advanced diagnostic CLIA-certified service laboratory developing novel tests for the oncology community, today announced the availability of OncoCEE-BR(TM) for breast cancer, a test designed to detect circulating tumor cells (CTCs) found in the blood of patients with this disease, and to assess their HER2/neu status by fluorescence in situ hybridization (FISH) performed on the CTCs detected in the blood. HER2/neu status is...

2011-07-15 17:17:00

SAN DIEGO, July 15, 2011 /PRNewswire/ -- Biocept, Inc. announced today that it has appointed William G. Kachioff as Senior Vice President, Finance and Chief Financial Officer. As CFO, Mr. Kachioff will be responsible for management of the company's accounting, finance, treasury, investor relations, risk management and information systems functions. Kachioff has more than 20 years of leadership experience in helping to build life science companies. Prior to joining Biocept, Kachioff was...

2011-06-02 14:46:00

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Data to be presented in a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois June 3-7 by researchers from The University of Texas MD Anderson Cancer Center and Biocept, Inc. show that a laboratory test developed by Biocept, Inc. for the evaluation of HER2 status of Circulating Tumor Cells (CTCs) and Disseminated Tumor Cells (DTCs) can provide potentially valuable information to...

2011-06-02 14:34:00

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Biocept, Inc. today reported that its scientists and academic collaborators will present a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois June 3-7. The poster presentation is based on studies performed utilizing Biocept's proprietary OncoCEE(TM) (Oncology Cell Enrichment and Extraction) technology platform for the capture, detection, enumeration and analysis of circulating tumor...

2011-05-24 06:30:00

RARITAN, N.J., May 24, 2011 /PRNewswire/ -- Veridex, LLC today announced the launch of the CELLTRACKS® Circulating Melanoma Cell (CMC) kit, providing research scientists with a fast, convenient and reliable way to capture CMCs for research studies. Using proprietary immunomagnetic technology to capture and count CMCs, the CELLTRACKS® CMC kit is designed to offer data that support researchers engineering investigational therapies that are based on a...

2011-05-20 07:28:06

(Ivanhoe Newswire) -- Researchers at Georgetown Lombardi Comprehensive Cancer Center say the amount of circulating tumor cells (CTCs) in the blood is a "powerful predictor" and reliable for aiding physicians when they assess treatment benefit for patients with metastatic breast cancer. "The current standard of care for monitoring patients with metastatic breast cancer involves the use of radiology studies such as CT scans, ultrasounds, and the like to determine whether or not patients are...

2011-05-19 11:05:29

Testing for circulating tumor cells helps inform clinical decisions about treatments and expensive radiologic scans Researchers at Georgetown Lombardi Comprehensive Cancer Center say the number of circulating tumor cells (CTCs) in the blood is a "powerful predictor" to help physicians more reliably assess treatment benefit for patients with metastatic breast cancer. The findings from a large analysis using pooled data from international cancer centers will be presented during a poster session...

2011-05-10 10:58:00

SAN DIEGO, May 10, 2011 /PRNewswire/ -- Biocept, Inc., a privately-held laboratory testing company focused on the detection, enumeration and analysis of circulating tumor cells (CTCs) in cancer patients, today announced the publication of a paper describing the identification of different CTC phenotypes using its proprietary Cell Enrichment and Extraction (CEE(TM)) platform. The paper, appearing in the Journal of Oncology and entitled "Detection of EPCAM-Negative and Cytokeratin-Negative...

2011-04-19 16:51:51

A $300,000 two-year grant from the Avon Foundation for Women will help researchers in the NCI-designated Dan L. Duncan Cancer Center at Baylor College of Medicine determine how breast cancer cells spread from the breast and target the brain. "This a very serious, and most fatal aspect of breast cancer. Presently, we cannot cure it," said Dr. Dario Marchetti, professor of pathology and immunology at BCM, and the principal investigator of the project.Seeds of cancer metastasis Marchetti directs...